caficrestat: Clinical Trials

3 trials of caficrestat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed, 1 terminated. 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Active not recruiting 1, Completed 1, Terminated 1
Phase 11Terminated 1

Follow caficrestat: new trials by email Literature Review of caficrestat trials Research Report on caficrestat

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)
NACA - Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain
Phase 2Active not recruitingArctic Therapeutics152024-04-032026-07-21
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
Eribulin Mesylate, Grapiprant - Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center62021-12-212025-06-13
Cardiovascular Effects of COVID-19
AT-001 - COVID-19
Phase 2CompletedNYU Langone Health812020-04-082021-09-16

Conditions studied

COVID-19 (1)  ·  Cerebral Amyloid Angiopathy, Familial (1)  ·  Cerebral Hemorrhage (1)  ·  Dementia (1)  ·  Inflammatory Breast Neoplasms (1)  ·  Intracranial Hemorrhages (1)

Sponsors

Arctic Therapeutics (1)  ·  M.D. Anderson Cancer Center (1)  ·  NYU Langone Health (1)

Countries

United States (2)  ·  Iceland (1)

Top investigators

Sadia Saleem (1)  ·  Stuart Katz, MD (1)

NIH funding

2023 (1)